Aptose to Participate in Cantor Oncology, Hematology & HemeOnc Conference
Aptose Biosciences (NASDAQ: APTO, TSX: APS) will participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28, 2022. Dr. Rafael Bejar, Chief Medical Officer, will join a panel discussion titled “Leukemia & MDS” and will conduct one-on-one meetings with attendees alongside CFO Fletcher Payne. The panel presentation is scheduled for 3:25 p.m. ET. Aptose is focused on developing oral kinase inhibitors for hematologic malignancies, boasting investigational products like HM43239 and luxeptinib aimed at improving treatment response.
- None.
- None.
SAN DIEGO and TORONTO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the Aptose will be participating in the Cantor Oncology, Hematology & HemeOnc Conference on September 28, 2022.
Dr. Rafael Bejar, Chief Medical Officer of Aptose, will participate in a panel, “Leukemia & MDS,” and with Mr. Fletcher Payne, CFO of Aptose, will be hosting one-on-one meetings during the conference. To schedule a one-on-one meeting with the Aptose management team, please contact your conference representative.
| Cantor Oncology, Hematology & HemeOnc Conference | |||
| Date: | September 28, 2022 | ||
| Presentation Time: | 3:25 p.m. ET | ||
| Format: | Panel Presentation | ||
| Participant: | Rafael Bejar, M.D., Ph.D., Senior Vice President, Chief Medical Officer | ||
About Aptose
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products under development for hematologic malignancies: HM43239, an oral, myeloid kinase inhibitor in an international Phase 1/2 trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib, an oral, dual lymphoid and myeloid kinome inhibitor in a Phase 1 a/b trial in patients with relapsed or refractory B-cell malignancies who have failed or are intolerant to standard therapies, and in a separate Phase 1 a/b trial in patients with relapsed or refractory AML or high-risk myelodysplastic syndrome (MDS). For more information, please visit www.aptose.com.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements relating to the Company’s growth, plans, objectives, expectations and intentions and other statements including words such as “continue”, “expect”, “intend”, “will”, “hope” “should”, “would”, “may”, “potential” and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release.
Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.
For further information, please contact:
| Aptose Biosciences Inc. | LifeSci Advisors, LLC | ||
| Susan Pietropaolo | Dan Ferry, Managing Director | ||
| Investor Relations | 617-535-7746 | ||
| 201-923-2049 | Daniel@LifeSciAdvisors.com | ||
| spietropaolo@aptose.com |
FAQ
What is Aptose's participation in the Cantor Oncology Conference on September 28, 2022?
Who will represent Aptose at the Cantor Oncology Conference?
What is the purpose of the one-on-one meetings at the conference?
What products is Aptose currently developing?
What is the focus of Aptose Biosciences?
